Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study
Dive into the research topics of 'Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study'. Together they form a unique fingerprint.
Keyphrases
Medicine and Dentistry
Pharmacology, Toxicology and Pharmaceutical Science